Clinical Trial Update: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-2206 (AKT inhibitor) with lapatinib and trastuzumab in unresectable locally advanced or metastatic HER2-positive breast, gastric, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)
• MK-2206 (MK-2206)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer | Phase 1 | Status: TERMINATED